NBI-98854

CAS# 171598-74-6

NBI-98854

Catalog No. BCC4278----Order now to get a substantial discount!

Product Name & Size Price Stock
NBI-98854: 5mg $368 In Stock
NBI-98854: 10mg Please Inquire In Stock
NBI-98854: 20mg Please Inquire Please Inquire
NBI-98854: 50mg Please Inquire Please Inquire
NBI-98854: 100mg Please Inquire Please Inquire
NBI-98854: 200mg Please Inquire Please Inquire
NBI-98854: 500mg Please Inquire Please Inquire
NBI-98854: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of NBI-98854

Number of papers citing our products

Chemical structure

NBI-98854

3D structure

Chemical Properties of NBI-98854

Cas No. 171598-74-6 SDF Download SDF
PubChem ID 44249892 Appearance Powder
Formula C19H29NO3 M.Wt 319.44
Type of Compound N/A Storage Desiccate at -20°C
Synonyms (2R,3R,11bR)-rel-Dihydrotetrabenazine; (2R,3R,11bR)-rel-DHTBZ
Solubility Soluble in DMSO
Chemical Name (2S,3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol
SMILES CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1O)OC)OC
Standard InChIKey WEQLWGNDNRARGE-XIRDDKMYSA-N
Standard InChI InChI=1S/C19H29NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16-17,21H,5-7,10-11H2,1-4H3/t14-,16-,17-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of NBI-98854

DescriptionNBI-98854 is a potent, highly selective, VMAT2 inhibitor that is effective in regulating the levels of dopamine release during nerve communication. IC50 value: Target: VMAT2 NBI-98854 completed a Phase I single ascending dose clinical trial in healthy male volunteers in Canada under an approved Clinical Trial Application with Health Canada.This trial showed NBI-98854 to be generally safe and well tolerated.

References:
[1]. NBI-98854 - Vesicular Monoamine Transporter 2 Inhibitor (VMAT2).

NBI-98854 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

NBI-98854 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of NBI-98854

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.1305 mL 15.6524 mL 31.3048 mL 62.6096 mL 78.262 mL
5 mM 0.6261 mL 3.1305 mL 6.261 mL 12.5219 mL 15.6524 mL
10 mM 0.313 mL 1.5652 mL 3.1305 mL 6.261 mL 7.8262 mL
50 mM 0.0626 mL 0.313 mL 0.6261 mL 1.2522 mL 1.5652 mL
100 mM 0.0313 mL 0.1565 mL 0.313 mL 0.6261 mL 0.7826 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on NBI-98854

NBI-98854 is a potent, highly selective, VMAT2 inhibitor that is effective in regulating the levels of dopamine release during nerve communication.

Featured Products
New Products
 

References on NBI-98854

NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.[Pubmed:26346941]

Mov Disord. 2015 Oct;30(12):1681-7.

BACKGROUND: Tardive dyskinesia is a persistent movement disorder induced by chronic neuroleptic exposure. NBI-98854 is a novel, highly selective, vesicular monoamine transporter 2 inhibitor. We present results of a randomized, 6-week, double-blind, placebo-controlled, dose-titration study evaluating the safety, tolerability, and efficacy of NBI-98854 for the treatment of tardive dyskinesia. METHODS: Male and female adult subjects with moderate or severe tardive dyskinesia were included. NBI-98854 or placebo was given once per day starting at 25 mg and then escalated by 25 mg to a maximum of 75 mg based on dyskinesia and tolerability assessment. The primary efficacy endpoint was the change in Abnormal Involuntary Movement Scale from baseline at week 6 scored by blinded, central video raters. The secondary endpoint was the Clinical Global Impression of Change-Tardive Dyskinesia score assessed by the blinded investigator. RESULTS: Two hundred five potential subjects were screened, and 102 were randomized; 76% of NBI-98854 subjects and 80% of placebo subjects reached the maximum allowed dose. Abnormal Involuntary Movement Scale scores for NBI-98854 compared with placebo were significantly reduced (p = 0.0005). Active drug was also superior on the Clinical Global Impression of Change-Tardive Dyskinesia (p < 0.0001). Treatment-emergent adverse event rates were 49% in the NBI-98854 and 33% in the placebo subjects. The most common adverse events (active vs. placebo) were fatigue and headache (9.8% vs. 4.1%) and constipation and urinary tract infection (3.9% vs. 6.1%). No clinically relevant changes in safety assessments were noted. CONCLUSION: NBI-98854 significantly improved tardive dyskinesia and was well tolerated in patients. These results support the phase 3 clinical trials of NBI-98854 now underway.

Description

Trans (2,3)-Dihydrotetrabenazine ((2R,3R,11bR)-rel-Dihydrotetrabenazine), a metabolite of Tetrabenazine, shows remarkable inhibition activity on vesicular monoamine transporter (VMAT2).

Keywords:

NBI-98854,171598-74-6,(2R,3R,11bR)-rel-Dihydrotetrabenazine; (2R,3R,11bR)-rel-DHTBZ,Natural Products,Monoamine transporter, buy NBI-98854 , NBI-98854 supplier , purchase NBI-98854 , NBI-98854 cost , NBI-98854 manufacturer , order NBI-98854 , high purity NBI-98854

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: